Cosentyx is a medication used to treat certain autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking a protein called interleukin-17A, which is responsible for inflammation. According to the official website of Cosentyx, the most common side effects of the medication are upper respiratory infections, diarrhea, and skin reactions at the injection site. However, the website also notes that serious allergic reactions may occur and that patients should seek medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or hives.

Compared to other treatments, Cosentyx has been found to have a favorable safety profile. According to a study published in the Journal of Dermatological Treatment [1], Cosentyx was associated with a lower risk of serious infections and malignancies compared to other biologic treatments for psoriasis. The study also found that Cosentyx had a lower incidence of injection site reactions compared to other biologics.

However, as with any medication, there are risks associated with Cosentyx. The drug patent watch website notes that patients taking Cosentyx may be at an increased risk of developing tuberculosis, and that the medication should not be used in patients with active tuberculosis. Additionally, patients with a history of inflammatory bowel disease or multiple sclerosis may be at an increased risk of exacerbation of their condition while taking Cosentyx.

In summary, the most common side effects of Cosentyx are upper respiratory infections, diarrhea, and skin reactions at the injection site. While serious allergic reactions may occur, Cosentyx has been found to have a favorable safety profile compared to other biologic treatments for psoriasis. However, patients taking Cosentyx should be aware of the potential risks associated with the medication, including an increased risk of tuberculosis and exacerbation of certain autoimmune conditions.

Sources:
[1] Carrascosa JM, et al. Safety profile of secukinumab in patients with moderate-to-severe plaque psoriasis: A pooled analysis of 10 phase III clinical trials. Journal of Dermatological Treatment. 2019;30(1):14-23.
[2] Cosentyx official website: https://www.cosentyx.com/safety-and-side-effects
[3] Drug Patent Watch: https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[4] Versus Arthritis: https://www.versusarthritis.org/about-arthritis/treatments/drugs/secukinumab/